Context: Acid labile subunit (ALS) deficiency, caused by IGFALS mutations, is a subtype of primary IGF-I deficiency (PIGFD) and has been associated with insulin resistance (IR) and osteopenia. Whether patients respond to recombinant human IGF-I (rhIGF-I) is unknown.
A cid labile subunit (ALS) forms the ternary complex with IGF-I and IGF binding protein 3 (IGFBP-3). The ternary complex prolongs serum half-life and metabolic actions of IGF-I. The ALS protein is synthesized in the liver and encoded by the IGFALS gene (chromosome 16p13.3). Mutations in IGFALS cause ALS deficiency, an autosomal recessive condition that is recognized as a subtype of primary IGF-I deficiency (PIGFD). Subjects with ALS deficiency are short but less so than other types of PIGFD and typically have low levels of ALS, IGF-I. and IGFBP-3, usually accompanied by compensatory elevated levels of GH (1) (2) (3) (4) . The less severe phenotype is best explained by the fact that only endocrine (circulating) IGF-I is low due to a typically decreased serum half-life, whereas tissue (skeletal) IGF-I production and action is maintained through elevated GH secretion.
Recombinant human IGF-I (rhIGF-I) is licensed for the treatment of PIGFD. However, the short half-life of endocrine IGF-I in ALS-deficient patients raises the question whether they can respond to rhIGF-I because both endogenous and exogenous IGF-I are predicted to clear rapidly from the circulation.
Biallelic mutations in IGFALS have also been associated with insulin resistance (IR) (1-3, 5-7) and low bone mass (2, (7) (8) (9) , likely as a result of low IGF-I and high GH levels. We have previously reported IGFALS gene dosage effects on growth (10), suggesting both IGFALS alleles need to be functionally active to allow normal endocrine IGF-I action. If gene dosage effects also apply to IR and bone strength, then affected families may potentially be at higher risk of developing diabetes, cardiovascular complications, and osteoporosis. Therefore, this study set out to investigate IGFALS gene dosage effects on IGF-I and insulin metabolism and body composition as well as bone geometry and density.
Aims
The primary objective of this study was to determine the pharmacokinetic (PK) and pharmacodynamic (PD) effects of a single sc injection of rhIGF-I on serum IGF-I concentrations in ALS-deficient patients. Secondary objectives included comparisons of IGF-I metabolism, IR, glucose handling, lipid profile, body composition, and bone geometry and density between ALS-deficient patients and their heterozygous first-degree relatives.
Subjects and Methods

Clinical characteristics
Four families with children known to have ALS deficiency were approached to take part in the study. All siblings and parents agreed to be genetically screened for IGFALS mutations.
Four ALS-deficient patients and 12 heterozygous carriers confirmed by screening agreed to take part in the study. All family members were of Sikh Indian origin, living in the United Kingdom. Clinical information obtained included a history of diabetes, medication, and low-trauma fractures. Written informed consent was obtained from all participants and their guardians.
Study design
This was an open-label, PK/PD study consisting of a single sc dose of rhIGF-I and a 14-hour period of serial blood sampling. The secondary objectives were met by a cross-sectional design, performing iv glucose tolerance tests, fasting blood, and bone analysis on the patients and their heterozygous first-degree family members. The participants were admitted to the National Institute for Health Research Wellcome Trust Clinical Research Facilities at the University Hospital Birmingham or Birmingham Children's Hospital. The study was approved by the regional ethics committee.
Anthropometry
Height (centimeters) and weight (kilograms) were measured using a wall-mounted stadiometer and electronic scales, respectively. Z-scores for age and gender were calculated using the 1990 UK growth reference data (11) . Z-scores for the body mass index (BMI) (kilograms per square meter) were calculated according to UK reference data (12) . Data for adult subjects were calculated as for 23 year olds.
Molecular genetic analysis
Mutation analysis of the IGFALS gene was performed after informed consent. DNA was extracted from whole blood using Puragene DNA purification system (Gentra Systems). The two exons and exon-intron boundaries of IGFALS were sequenced as previously described (13, 14) .
PK response to rhIGF-I
Patients with ALS deficiency were admitted after fasting overnight. An indwelling venous catheter was placed and baseline blood levels for IGF-I, free IGF-I, IGFBP-3, GH, ALS, cholesterol, triglycerides, glucose, and insulin measurement taken at 8:00 AM. Two further baseline blood levels were taken for IGF-I, free IGF-I, IGFBP-3, and GH within the next 59 minutes, and results were averaged for analysis. A sc injection of rhIGF-I (mecasermin, Increlex; Ipsen) was administered in a standard dose of 120 g/kg at 9:00 AM. A morning meal was then provided, and Lucozade was kept at the bedside to prevent and, if necessary, to treat hypoglycemia. Blood samples for IGF-I, free IGF-I, IGFBP-3, and glucose were repeated at 9:30 AM, 10:00 AM, 10:30 AM, 11:00 AM, 11:30 AM, 12:00 PM, 1:00 PM, 2:00 PM, 4:00 PM, 6:00 PM, 8:00 PM, and 10:00 PM. Meals were taken at 9:10 AM, 4:00 PM, and 8:00 PM only, with free access to water and blood glucose monitoring.
Analysis of IGF-I metabolism
For analysis of IGF-I metabolism, blood samples were centrifuged to obtain serum, kept frozen at Ϫ70 to Ϫ80°C, and sent collectively on dry ice to the following laboratories. IGF-I, IGFBP-3, free IGF-I, and GH were analyzed at Aarhus University (Aarhus, Denmark). Free IGF-I was determined by ultracentrifugation performed at 37°C in undiluted serum as previously described (15) . The ultrafiltrates were assayed for free IGF-I using an in-house IGF-I immunoassay (16) 
Insulin, glucose, and lipid metabolism
An iv glucose tolerance test was performed on all subjects according to published standards (17) . Subjects were admitted after fasting overnight. After cannulation and baseline sampling for glucose and insulin (Ϫ5 minutes), a glucose infusion of 0.5 g/kg body weight (maximum 35 g) was given as a 25% solution over 3 minutes. Subsequent samples were taken immediately after the infusion (0 minutes) and after 1, 3, 5, 10, 15, 30, 45, and 60 minutes. Glucose disappearance rate (k) and half-life (t ½ ) were calculated. A k value less than 1% confirms diabetes, whereas a k value between 1.0% and 1.2% constitutes impaired glucose tolerance. First-phase and second-phase insulin secretions were calculated as the integral [area under the curve (AUC)] of insulin concentrations stimulated above the fasting level for the first 10 minutes (0 -10 min AUC) and the remaining time (10 -60 min AUC), respectively. Diagnostic American Diabetes Association standards for fasting glucose and diabetes (18) and references data for fasting insulin (19) were used for interpretation.
Glucose, cholesterol, and triglycerides were measured locally using an Olympus AU640 spectrophotometric analyzer supported by Beckham Coulter. Insulin was measured using a Mercodia Iso-Insulin ELISA (Mercodia AB), which is a solid-phase, two-site ELISA with intra-and interassay coefficients of variation of 3.0% and 3.9%, respectively. Analysis of insulin was performed at the SAS Peptide Laboratory. Individual paired glucose and insulin levels were entered into the homeostasis model assessment (HOMA)-2 model (20) to estimate ␤-cell function (%B) and insulin sensitivity (%S).
Bone size, density, and body composition
Dual-energy X-ray absorptiometry (DXA)
DXA scans of the lumbar spine (L1-4) and total body were performed on a GE Lunar iDXA scanner according to standard protocols. To avoid size-related DXA artifacts typical for individuals with short stature, age-and gender-specific results for bone mineral content [BMC (grams)] and density [BMD (grams per square centimeter)] and lean tissue mass (LTM) require correction for body size. Size corrections involved the calculation of the bone mineral apparent density [BMAD (grams per cubic centimeter)] for the lumbar spine (21) as well as the appropriate adjustments of BMC for LTM and height for the total body scan (22) .
Peripheral quantitative computed tomography (pQCT)
The pQCT analysis was performed at the distal (4% of radial length) and proximal radius (65% of radial length) on the nondominant forearm using an XCT-2000 device (Stratec). Age-and gender-specific Z-scores were calculated using reference data for children and adults younger than 40 years (23, 24) or older than 40 years (25, 26) . Outcome variables analyzed included trabecular and total volumetric BMD (grams per cubic centimeter) at the distal radius as well as cortical density and thickness, BMC, muscle area, and the ratios BMC to muscle and cortical to total cross-sectional area at the proximal radius.
Radiogrammetry
Standard left-hand X-rays were taken of all study participants and analyzed in DICOM format using the BoneXpert software (Visiana; www.BoneXpert.com). Metacarpal (MC) length and width, cortical thickness, medullary diameter, and bone age were measured. Results were available as gender-specific Z-scores for both chronological age and bone age for subjects younger than 20 years (27) . For adults older than 20 years, Z-scores were calculated according to adult reference data (28) . Z-scores for MC length for adults were calculated as for a 19 year old. To correct for body size, the pediatric bone index [PBI; cortical area/ (width 1.33 length 0.33 )] was applied, which puts MC length and width into proportion (29) . PBI Z-scores for age and gender were calculated according to Martin et al (27) .
Statistical analysis
The response to rhIGF-I in the PK/PD study was analyzed in several ways. The maximum concentrations of IGF-I, IGFBP-3, and free IGF-I (Cmax) and the time they occurred after injection (Tmax) as well as the maximum increment from the averaged baseline values (⌬) was recorded. The 12-hour AUC of IGF-I, free IGF-I, and IGFBP-3 after the injection, and respective elimination rates (k el ) and t ½ were calculated. ANOVA for repeated measures was used to analyze the longitudinal changes in IGF-I metabolites, the ratio of free to total IGF-I, and the molar ratio of IGF-I to IGFBP-3 during the 14-hour PK/PD study. Results for IGF-I and IGFBP-3 were compared with previously presented data on three individuals with severe PIGFD (Laron syndrome), three with moderate PIGFD (IGF-I Z-score Ϫ3 to Ϫ2), and three normal controls (IGF-I Z-score Ͼ Ϫ2) by one-way ANOVA and post hoc Tukey tests. These data were taken from a previous study using the same rhIGF-I dose and similar study design (30) and kindly supplied by Ipsen (United Kingdom). Comparison of Z-scores of patients or carriers with the relevant reference population (zero) was done by one-sample t test or Wilcoxon signed rank test, as appropriate.
The Mann-Whitney U (MWU) test was used to compare all cross-sectional parameters between the patients (n ϭ 4) and heterozygous carriers (n ϭ 12). To correct total body BMC for body size, analysis of covariance was performed using LTM or height as covariates. Values of P Ͻ .05 were considered significant.
Results
Cohort characteristics and IGF-I metabolism
The four ALS-deficient patients (aged 7.9, 10.3, 19.1, and 21.4 y) had originally presented to pediatric endocrinologists with short stature. Their birth weights ranged from 1970 to 3075 g (Z-scores Ϫ3.09 to Ϫ1.57). Table 1 shows the anthropometric and biochemical parameters of the GH/IGF-I axis of the four patients and their 12 heterozygous first-degree relatives. Patients were significantly shorter and lighter relative to carriers. In the patients, ALS was undetectable, and free and total IGF-I and IGFBP-3 concentrations were very low, with a compensatory increase in GH levels. Heterozygote carriers had intermediate IGF-I peptide levels and normal GH. Gene dosage effects were observed for height, free and total IGF-I, IGFBP-3, and ALS. None of the study participants had experienced low-trauma fractures. One carrier was a known type 2 diabetic.
We have previously reported the molecular genetic results of three of the four families (13, 14) . Patient 1 was homozygous for the IGFALS missense mutation P73L. Patient 2 was a compound heterozygote for the missense mutation L134Q and a GGC-to-AG substitution at position 546 -548 (546 -548delGGCinsAG). The latter causes a frameshift and the appearance of a premature stop codon. The fourth family included patients 3 and 4 (prepubertal siblings) who were homozygous for the L134Q mutation.
Response to rhIGF-I
IGF-I and IGFBP-3 increased significantly above baseline (P Ͻ .05) for a duration of 2.5 hours and dropped to baseline levels 7 hours after the rhIGF-I injection. Figure  1 , A and B, compares IGF-I and IGFBP-3 responses to 120 g/kg rhIGF-I of ALS deficient patients with published data on patients with severe and moderate PIGFD as well as healthy controls. The elimination rate and half-life of IGF-I in ALS deficiency was comparable with those reported for severe PIGFD. However, the IGF-I increment (P ϭ .019) and 12-hour AUC (P ϭ .049) were significantly lower, with similar trends in Cmax and Tmax. As expected, all major PK parameters for IGF-I were significantly lower in ALS deficiency compared with the moderate PIGFD and healthy control groups ( Table 2 ). The IGFBP-3 response to rhIGF-I in the ALS-deficient patients was similar to those with severe PIGFD.
Mean (SD) IGF-I Z-score increased by 2.49 (0.90), whereas IGFBP-3 Z-score increased by 0.57 (0.10) only (Figure 2, C and E). Postinjection IGF-I Z-scores above Ϫ2 were sustained for 2.5-12 hours, whereas the IGFBP-3 Z-score remained consistently below Ϫ4 in all four ALSdeficient patients. In addition, circulating rhIGF-I remained predominantly unassociated as free IGF-I, and the ratios of free to total IGF-I and IGF-I to IGFBP-3 increased significantly (P Ͻ .05) and demonstrated comparable PK profiles ( Figure 2, B, D, and F) . The two prepubertal patients had higher IGFBP-3 Z-scores, lower free and total IGF-I Cmax, and a generally lower PK response in IGF-I and free IGF-I compared with the two young adult patients (Figure 2) .
Insulin, glucose, and lipid metabolism
Three (of four) ALS-deficient patients had elevated fasting insulin levels and HOMA-IR values greater than 2, one of whom had impaired fasting glucose. All patients had normal k values. The oldest patient had the highest BMI, percentage body fat Z-score, fasting insulin, and HOMA-IR values. Percentage body fat Z-score correlated with insulin, first-and second-phase insulin response, and HOMA-IR Results are given as median (range) and groups were compared by the MWU test. a P Ͻ .01, significant differences for comparison of age-and gender-specific Z-scores with the reference population (zero).
b P Ͻ .001, significant differences for comparison of age-and gender-specific Z-scores with the reference population (zero).
c P Ͻ .05, significant differences for comparison of age-and gender-specific Z-scores with the reference population (zero).
d Reference range for healthy young adults for free IGF-I is median 0.85 g/L (range 0.46 -1.92).
(P Ͻ .05) in patients but not in carriers. Six (of 12) heterozygous carriers had abnormalities in glucose metabolism. Two carriers (aged 53 and 55 y) were diabetic and another (aged 29 y) had impaired glucose tolerance (k value, 1.07%; fasting insulin, 283 pmol/L; fasting glucose, 6.8 mmol/L). Elevated fasting insulin was found in another carrier and borderline impaired fasting glycemia (plasma glucose 5.6 -6.9 mmol/L) of 5.6 mmol/L without hyperinsulinism in two others. Overall, however, there were no significant differences in fasting glucose, insulin, first-or second-phase insulin response, glucose disappearance rates, and HOMA-IR as well as fasting lipids between ALS-deficient patients and carriers (Table 3 ).
Bone geometry and density
As expected, ALS-deficient patients had lower bone density readings in 2-dimensional imaging but normal readings in 3-dimensional imaging (Table 4) . ALS-deficient patients had similar lumbar spine BMAD and total body BMD Z-scores using DXA as well as total, trabecular, and cortical density Z-scores using pQCT, compared with carriers. In contrast, total body and radial BMC was significantly lower in ALS-deficient patients compared with carriers. This difference in BMC did not persist after correction for height or LTM (total body) and muscle area (radius). There was a gene dosage effect on muscle area Zscore (P Ͻ .001), but the forearm BMC to muscle area ratio was not different between groups.
Bone size (MC length and width) was significantly smaller in the ALS-deficient patients compared with carriers, demonstrating that both growth in bone length and width is compromised. MC width was affected by a gene dosage effect with significant differences among patients (Ϫ2.48 SD), carriers (Ϫ1.28 SD), and the reference population (all P Յ .001). Similarly, cortical thickness at the radius and the metacarpus in patients tended to be lower compared with carriers or with zero. Although the CA to TA ratio, MC medullary diameter, and PBI were not different between groups, the PBI Z-score was reduced in ALS-deficient patients (Ϫ1.26 SD, P ϭ .032). Bone widening appeared more affected than bone elongation because Z-scores for MC width were generally lower than those for MC length in both ALS-deficient patients (P ϭ .068) and carriers (P ϭ .005).
Discussion
We previously reported IGFALS gene dosage effects on height (10). Here we demonstrate similar gene dosage effects on IGF-I, IGFBP-3, ALS, free IGF-I, forearm muscle area, and MC width. Based on these results, we conclude that one functional IGFALS allele is not sufficient to maintain normal ALS levels, endocrine IGF-I action, full growth potential, muscle size, and periosteal expansion. In addition, our results suggest similar gene dosage effects may exist for parameters of IR. Despite similar elimination pharmacokinetics, subjects with ALS deficiency respond less to rhIGF-I treatment compared with patients with severe PIGFD.
PK response to rhIGF-I
The PK elimination of rhIGF-I in ALS-deficient subjects was comparable with patients with severe PIGFD (30) , but the increment and extent of the PK response (⌬-and 12 h AUC IGF-I) were lowest among all groups. Free IGF-I increased after the injection but remained unassociated with IGFBP-3 and ALS. Hence, more free IGF-I is available for anabolic action, which demonstrates a response to treatment. Although IGF-I levels remained above baseline for more than 7 hours after the injection, normal IGF-I Z-scores (ϾϪ2SD) were achieved for only 3-13 hours, and the response was lower in prepubertal patients. Therefore, if rhIGF-I were to be used as a treatment for ALS deficiency, three injections per day or the administration of rhIGF-I by continuous sc pump infusion (31) may be more efficacious than twice-daily injections. Given the moderate degree of final height reduction of ALS-deficient subjects compared with other PIGFD disorders, the costs/ benefit and risk/benefit of such treatment would need to be considered in the light of the known side effect profile of rhIGF-I.
Insulin resistance
IR is a feature of PIGFD disorders (32, 33) , but type 2 diabetes appears uncommon (34) and associated with obesity (35, 36) . Although elevated GH levels are typical for PIGFD and associated with a diabetogenic profile, the low circulating IGF-I is the more likely cause of IR in individuals with PIGFD. Defective IGF-I receptor signaling is a well-recognized cause of IR, impaired glucose uptake in skeletal muscle, and type 2 diabetes (37) (38) (39) . Therefore, the lack of the circulating receptor ligand (endocrine IGF-I) should induce similar effects. In fact, several elegant mouse models demonstrate that low endocrine IGF-I causes IR (40 -42) , whereas IGF-I normalization restores glucose tolerance (32, 43, 44) . However, the ALS knockout (ALSKO) mouse is not insulin resistant and not GH hypersecretive (41, (45) (46) (47) . Therefore, the exact mechanisms involved in the cross talk between insulin, IGF-I, and their receptors are complex (32) , and extrapolation of data from animal models to human physiology is limited.
Contrary to the ALSKO mouse model, most reports of patients with biallelic IGFALS mutations describe IR as a feature, although none describes overt diabetes (1-3, 5-7, 48). Gene dosing effects on IR in our study were present but less clear compared with those on IGF-I metabolism. Three of our four ALS-deficient patients (75%) had evidence of abnormal glucose metabolism compared with 6 of 12 carriers (50%). Because carriers were significantly older and heavier for age and both factors are associated with development of IR and type 2 diabetes, comparison of the two groups is not straightforward. In addition, because type 2 diabetes is more common in Asians, our results are not necessarily indicative of a higher diabetes risk in carriers. Naturally, given that ALS deficiency is a very rare condition, any study would currently be underpowered to detect more modest differences. Whether IR caused by IGFALS gene mutations responds to rhIGF-I or metformin warrants further studies.
Bone health
Low bone mass was previously reported in subjects with ALS deficiency (2, 7-9), but DXA results were not adjusted for body size, which leads to a misinterpretation of size artifacts (49, 50) . We demonstrate that appropriately size-adjusted bone density in ALS-deficient subjects and carriers is normal, but bone size and mass are natu- Results are given as mean (SD). The P value relates to the results of one-way ANOVA. a P Ͻ .05, differences compared with the ALS-deficient group only.
rally decreased due to short stature. In addition, we are the first to describe the effect of IGFALS mutations on bone compartment density and geometry and muscle size in humans. Bone widening (periosteal expansion) was reduced out of proportion relative to bone elongation (growth), creating a slender bone phenotype. Subperiosteal bone formation and endosteal resorption are the two processes that define cortical thickness, width, and medullary diameter of long bones. Our finding of IGFALS gene dosage effects on bone width but normal density is not unexpected, given that reduced cortical thickness is the only consistent bone deficit in humans and animals models of GH deficiency (50) . In addition, children and adults with GH deficiency or PIGFD have consistently lower Z-scores for muscle compared with bone measures (50) . Because IGF-I is anabolic to muscle and muscle force is the main driver of periosteal expansion according to the mechanostat concept (51), we are unable to determine whether the observed bone phenotype is primarily endocrine or secondary to low muscle pull. Various mouse models have recently clarified that endocrine IGF-I is the main stimulant of subperiosteal bone formation, whereas skeletal integrity and bone density are controlled by tissue IGF-I (41, 46, 47, 52, 53) . ALS deficiency creates a unique biochemical profile because the low endocrine IGF-I triggers GH hypersecretion (1), which stimulates tissue IGF-I. Slender bones are typical for all GHD and PIGFD mouse models, whereas trabecular bone is unaltered (50) . However, reports on the ALSKO mouse model, which does not feature GH hypersecretion, vary in that respect (41, 46, 47) , so again, extrapolation to human physiology needs to be questioned. Low-impact fractures were not a feature of our cohort and not unexpectedly because even the most severe, long-standing disorders of GHD and PIGFD are not associated with an increased fracture risk (50) . Similarly, mouse models of low endocrine IGF-I do not indicate long-term skeletal risks of the slender bones (53, 54) . Contrary to the concept of high endocrine IGF-I promoting musculoskeletal health, low endocrine IGF-I may be protective for longevity through the reduction in oxidative stress-induced tissue damage (55) . Hardly any evidence exists on the long-term cardiovascular risk of individuals with ALS deficiency or heterozygous carriers. Premature cardiovascular risk was not found in one young adult ALS-deficient patient (48) . Although lipid status was normal in our cohort, the increased prevalence of IR, impaired glucose tolerance, and diabetes warrants long-term follow-up of subjects with both biallelic and heterozygous IGFALS mutations. Limitations of this study include the naturally small subject numbers and the lack of ethnically specific reference databases for bone imaging, growth, and all biochemical measurements. In addition, although the families were not knowingly consanguineous or interrelated, three of the four patients were homozygous for a specific IGFALS mutation, suggesting common ancestry. Genome-wide, recessive inbreeding effects can account for up to 3 cm in adult height (56) . The final height reached by two of our male patients (149.2 and 159 cm), compared with the average male carrier height of 167.6 cm (n ϭ 7), suggest the effect on height of one additional IGFALS mutation is stronger than other recessive genome-wide effects.
In conclusion, we demonstrate IGFALS gene dosage effects on IGF-I metabolism, height, muscle size, and MC bone width, with similar gene dosage trends for IR and abnormal glucose handling, and provide conclusive PK response data for this PIGFD subtype. Similar to humans with, and mouse models of, GHD or PIGFD, we found no evidence of reduced size-corrected bone density or lowimpact fractures. ALS deficiency creates a phenotype of slender bones of normal density. Evidence gained from our study indicates that individuals carrying IGFALS gene mutations may be a risk group for diabetes.
